About The Study: In this study that included 167,000 non-hospitalized patients, neutralizing monoclonal antibody (nMAb) treatment for COVID-19 was safe and associated with reductions in emergency department visits, hospitalization, and death, although it was not associated with reduced risk of hospitalization during the Omicron BA.1 epoch. These findings suggest that targeted risk stratification strategies may help optimize future nMAb treatment decisions.
Authors: Brian Anderson, M.D., of the MITRE Corporation in Bedford, Massachusetts, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.9694?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=042423
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open